Gilead Sciences, Inc.

NASDAQ:GILD  
66.54
0.00 (0.00%)
4:40:25 PM EDT: $66.54 0.00 (0.00%)
Products, Regulatory

Humanigen Says Drug Improves Ventilator-Free Survival In Covid-19 Patients

Published: 03/29/2021 11:45 GMT
Gilead Sciences, Inc. (GILD) - Humanigen Reports Positive Phase 3 Topline Results Showing Lenzilumab Improves Survival Without Need for Mechanical Ventilation in Hospitalized Patients With Covid-19.
Humanigen - Lenzilumab Achieved Primary Endpoint of Phase 3 Study.
Humanigen - Lenzilumab Improved the Relative Likelihood of Survival Without Need for Invasive Mechanical Ventilation by 54%.
Humanigen - Clinical Improvement With Lenzilumab Was Observed Over and Above Other Treatments, Including Steroidsand/or Remdesivir.
Humanigen - a Favorable Trend in Mortality Was Observed in the Lenzilumab Arm Compared With the Placebo Arm in Study.
Humanigen - Lenzilumab Appeared to Be Safe and Well-tolerated; No New Saes Were Identified, and None Were Attributed to Lenzilumabin Study.
Humanigen - Next Step is to Submit an Application for Eua to U.S. FDA As Soon As Possible.